Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.


Pulmonary arterial hypertension (PAH) is a rare debilitating disease characterized by an increase in pulmonary vascular resistance and progressive right ventricular failure. PAH may be primary or associated with other conditions such as collagen vascular disease, portal hypertension, and HIV. Intravenous epoprostenol improves the survival, exercise… (More)


  • Presentations referencing similar topics